# Gemin X Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gemin-x-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Montreal, Canada
- Website: www.geminx.com
- Total disclosed funding: $62M
- Latest round: Series E (Aug 24, 2010)
- Investors on record: 13

## About

Gemin X Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative therapies for cancer treatment, leveraging advanced research and technology to improve patient outcomes.Gemin X Pharmaceuticals Inc. was founded in 1998 in Montreal, Canada, and specializes in the development of novel cancer therapies. The company was acquired by Cephalon in March 2011 for USD 225 mn. Throughout its operations, Gemin X has completed a total of 5 deals, with the most recent deal occurring on March 21, 2011. The company operates independently under the Cephalon brand, which is now part of Teva Pharmaceuticals.Gemin X Pharmaceuticals Inc. specializes in developing advanced biopharmaceutical products aimed at treating cancer. Their core offerings include targeted therapies designed to optimize patient treatment regimens, specifically addressing various types of oncology-related conditions. These products are intended for healthcare providers and institutions seeking innovative solutions to improve treatment efficacy and patient care.Gemin X Pharmaceuticals Inc. generates revenue primarily through the sale of its oncology-focused product portfolios, which are marketed directly to healthcare providers. The company has established partnerships that allow for customized implementation of its therapies, enhancing their value proposition to healthcare clients. Revenue is further supported by ongoing contracts that ensure continuous product supply and support for healthcare providers.In the wake of its acquisition by Cephalon, Gemin X Pharmaceuticals plans to leverage the synergies from this partnership to expand its product offerings into additional cancer therapies. The company is currently exploring new formulations and treatment protocols for launch within the next two years. Additionally, Gemin X aims to penetrate markets in Europe and Asia by 2025, capitalizing on its innovative product pipeline. The recent acquisition funding will be utilized to support research and development initiatives and to facilitate the expansion into these new geographic regions.

## Funding rounds

- Series E, Aug 24, 2010, $8M — Sanderling Ventures, Valence Life Sciences
- Series D, Apr 20, 2010, $16M — Sanderling Ventures, Valence Life Sciences
- Series C, Jul 3, 2008, $38M — Sanderling Ventures, VantagePoint Capital, HBM Partners, BDC Capital, Pinnacle Ventures, Ontario Teachers' Pension Plan, Fonds de Solidarité des Travailleurs du Québec, H.I.G. BioHealth Partners, Valence Life Sciences, SB Life Science, ProQuest Investments, Merlin Nexus, Canadian Medical Discoveries Fund Inc.

## Investors

- Sanderling Ventures (https://capitalatlas.ai/funds/sanderling-ventures) — Series C, Series D, Series E
- VantagePoint Capital (https://capitalatlas.ai/funds/vantagepoint-capital) — Series C
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series C
- BDC Capital (https://capitalatlas.ai/funds/bdc-capital) — Series C
- Pinnacle Ventures (https://capitalatlas.ai/funds/pinnacle-ventures) — Series C
- Ontario Teachers' Pension Plan — Series C
- Fonds de Solidarité des Travailleurs du Québec — Series C
- H.I.G. BioHealth Partners (https://capitalatlas.ai/funds/h-i-g-biohealth-partners) — Series C
- Valence Life Sciences (https://capitalatlas.ai/funds/valence-life-sciences) — Series C, Series D, Series E
- SB Life Science (https://capitalatlas.ai/funds/sb-life-science) — Series C
- ProQuest Investments (https://capitalatlas.ai/funds/proquest-investments) — Series C
- Merlin Nexus (https://capitalatlas.ai/funds/merlin-nexus) — Series C
- Canadian Medical Discoveries Fund Inc. — Series C